Topic: squamous cell carcinoma
Sanofi and Regeneron's new immuno-oncology drug is the sixth PD-1 inhibitor to win FDA approval, but it has niche market to itself.
Sanofi and Regeneron have touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
Innate Pharma said it can’t see an obvious way to bring its cancer antibody lirilumab forward in development after it flunked a second clinical trial.
Kura Oncology shares are up 75% after the biotech reported hitting the mark in a phase 2 trial of tipifarnib—before the study was fully enrolled.